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Abstract
Aims/hypothesis Zfp69 was previously identified by positional
cloning as a candidate gene for obesity-associated diabetes.
C57BL/6J and New Zealand obese (NZO) mice carry a
loss-of-function mutation due to the integration of a
retrotransposon. On the NZO background, the Zfp69 locus
caused severe hyperglycaemia and loss of beta cells. To provide
direct evidence for a causal role of Zfp69, we investigated the
effects of its overexpression on both a lean [B6-Tg(Zfp69)] and
an obese [NZO/B6-Tg(Zfp69)] background.
Methods Zfp69 transgenic mice were generated by integrating
the cDNA into the ROSA locus of the C57BL/6 genome and
characterised.
Results B6-Tg(Zfp69) mice were normoglycaemic, developed
hyperinsulinaemia, and exhibited increased expression of G6pc
and Pck1 and slightly reduced phospho-Akt levels in the liver.
During OGTTs, glucose clearance was normal but insulin levels
were significantly higher in the B6-Tg(Zfp69) than in control
mice. The liver fat content and plasma triacylglycerol levelswere
significantly increased in B6-Tg(Zfp69) andNZO/B6-Tg(Zfp69)
mice on a high-fat diet compared with controls. Liver
transcriptome analysis of B6-Tg(Zfp69) mice revealed a down-
regulation of genes involved in glucose and lipid metabolism.
Specifically, expression ofNampt, Lpin2,Map2k6, Gys2, Bnip3,
Fitm2, Slc2a2,Ppargc1α and Insrwas significantly decreased in
the liver of B6-Tg(Zfp69) mice compared with wild-type ani-
mals. However, overexpression of Zfp69 did not induce overt
diabetes with hyperglycaemia and beta cell loss.
Conclusions/interpretation Zfp69 mediates hyperlipidaemia,
liver fat accumulation and mild insulin resistance. However,
it does not induce type 2 diabetes, suggesting that the
diabetogenic effect of the Zfp69 locus requires synergy with
other as yet unidentified genes.
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Multiple studies have demonstrated the shared contribution of
both genetic and environmental factors in the development of
type 2 diabetes mellitus [1, 2]. Genome-wide association and
linkage studies have markedly improved our understanding of
the genetic basis of type 2 diabetes in humans [3–5] and ro-
dents [6–10], respectively. In mouse studies, diabetogenic
quantitative trait loci (QTL) have been mapped by intercross
of inbred strains with diabetes-related phenotypes, leading to
the identification of several candidate genes for diabetes sus-
ceptibility or resistance [6, 8–10].
In an intercross of NON (non-obese non-diabetic) and
NZO (New Zealand obese) mice, Leiter et al mapped the
NON-derived diabetogenic locus Nidd1 to chromosome 4
[8]. This locus contributed substantially to the development
of hyperglycaemia and hypoinsulinemia [8]. A diabetogenic
locus partially overlapping with Nidd1 (Nidd/SJL) was iden-
tified in a backcross population of Swiss Jim Lambert (SJL)
and NZO mice. The SJL-derived QTL caused severe
hyperglycaemia and hypoinsulinaemia [9]. Moreover, when
combinedwith the obesity QTL,Nob1, the diabetogenic effect
fromNidd/SJLwas greatly enhanced by a high-fat diet (HFD),
which strongly suggests that Nidd/SJL contains a gene for
obesity-associated diabetes [9].
By sequencing and gene expression profiling of the critical
region of Nidd/SJL, we identified the zinc finger domain tran-
scription factor Zfp69 as the most likely candidate gene within
the QTL. Mouse strains such as SJL and NON carry the dia-
betogenic allele of Zfp69, which generates a normal full length
mRNA comprising a Krüppel-associated box (KRAB) and a
Znf-C2H2 domain [11]. By contrast, carriers of the
retrotransposon IAPLTR1a in intron 3 of Zfp69 (NZO,
C57BL/6J) produce a truncated mRNA and are less diabetes
prone (NZO) or fully protected (C57BL6/J) [11].
In order to provide additional evidence for a causal role of
Zfp69 and to investigate the mechanism of its diabetogenic
potency, we generated a transgenic mouse line overexpressing
the gene on the B6 and NZO×B6 background, and studied
glucose homeostasis and fat distribution. Zfp69 induced the
accumulation of liver fat and a mild insulin resistance,
confirming the role of Zfp69 as a diabetogenic gene.
Methods
Generation of a transgenic mouse line overexpressing
Zfp69 Zfp69 cDNA tagged with a C-terminal Myc epitope
was fused to the ubiquitin C promoter. For integration into
the ROSA locus, the construct was flanked by fragments cor-
responding with the sequence of this locus. A Zfp69 transgen-
ic mouse line was generated with C57BL/6J mice as back-
ground strain (Ozgene, Perth, Western Australia, Australia).
To generate obese NZO/B6 F1 hybrid mice, B6-Tg(Zfp69)
hemizygote male mice were mated with NZO/HIBomDife
female mice (R. Kluge, German Institute of Human Nutrition,
Nuthetal, Germany).
The animals were housed in a controlled environment (20±
2°C, 12 h/12 h light/dark cycle), fed a standard diet (SD;
V153x R/M-H, Ssniff, Soest, Germany) or a HFD (45% en-
ergy from fat, D12451, Research Diets, New Brunswick, NJ,
USA). All animal experiments were approved by the ethics
committee of the State Office of Environment, Health and
Consumer Protection (State of Brandenburg, Germany).
Study design Male mice [B6-wild-type (WT) and
B6-Tg(Zfp69); NZO/B6-WT and NZO/B6-Tg(Zfp69)] were
fed SD or HFD. Body weight and blood glucose levels
were measured weekly from 4 to 16 weeks of age, and
then every other week until 24 weeks of age. Body com-
position was analysed at 8 and 16 weeks of age by com-
puted tomography (CT). OGTT was performed at week
18. Animals were killed in a postprandial state at 24 weeks
of age and plasma insulin and pancreatic insulin content
were estimated.
Quantitative real-time PCR Total RNA was extracted and
cDNA synthesis was performed as described previously [12]
for quantitative real-time PCR (qPCR) via the LightCycler
480 system and FastStart Universal probeMaster mix (Roche,
Mannheim, Germany). Primers are listed in Electronic
Supplementary Material (ESM) Table 1.
Nuclear extract preparation and western blotting Liver
samples (8 weeks) were homogenised and nuclear extracts
were isolated by a kit according to manufacturer’s instructions
(Thermo Scientific NE-PER, Bonn, Germany). Nuclear ex-
tracts were analysed by western blot with a primary antibody
against ZFP69 [11]. For the detection of phospho-Akt (pAKT)
and total-Akt (tAKT), liver lysates were analysed by western
blot with antibodies against pAKT, tAKT, both raised in
rabbit, at 1:1,000 dilution (Merck Millipore, Darmstadt, Ger-
many) and β-actin raised in mouse at 1:5,000 dilution (Sigma,
Munich, Germany).
Plasma analysis Blood glucose was measured with a
Glucometer Elite (Bayer, Leverkusen, Germany). Insulin
was measured with ELISAs from DRG Diagnostics
(Marburg, Germany), and triacylglycerols were measured
with Triglyceride Reagent from Sigma. Measurements were
performed in a blinded manner.
Pancreatic insulin content and isolation of islets of
Langerhans Detection of total pancreatic insulin, isolation
of pancreatic islets and detection of glucose-stimulated insulin
secretion were determined as previously described [13].
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Quantification of beta cell area Pancreases were fixed in 4%
paraformaldehyde for 24 h. Evenly spaced 12 μm sections
were stained for insulin (DAKO, Hamburg, Germany) to de-
termine the beta cell area. Secondary Cy3-conjugated antibod-
ies (Life Technologies, Darmstadt, Germany) and DAPI
(Sigma) for cell-nuclei were used. The cross-sectional and
insulin-positive areas were quantified using Fiji/ImageJ (Fiji,
Dresden, Germany). Relative insulin-positive area was deter-
mined by quantification of cross-sectional insulin-positive ar-
ea divided by cross-sectional area of the whole pancreas and
presented as 100% of weight.
OGTT B6 mice were fasted for 6 h prior to an oral or intra-
peritoneal application of glucose (20% solution, 2 g/kg body
weight), while NZO/B6 were fasted for 16 h to reach basal
glucose levels before the application. Glucose and insulin
concentrations were detected at indicated time points.
Insulin tolerance test For the insulin tolerance test (ITT), B6-
WTand B6-Tg(Zfp69) mice (6 h fasted) were intraperitoneally
injected with insulin (1 U for SD; 1.25 U for HFD) and the
blood glucose levels were estimated from the tail-tips.
Immunohistochemistry Paraffin sections of the liver of
B6-WT and B6-Tg(Zfp69) mice were prepared as described
earlier [14]. Sections were incubated with anti-Plin2 antibody
(Progen Biotechnik, Heidelberg, Germany) in combination
with fluorescence-conjugated Alexa488-antibody (Life Tech-
nologies) and analysed with a Leica TCS SP2 Laser Scan
inverted microscope (Leica, Wetzlar, Germany).
CT CT was per formed us ing LaTheta LCT-200
(Hitachi-Aloka, Tokyo, Japan). Subcutaneous fat and visceral
fat of B6-WT and B6-Tg(Zfp69) at 8 and 16 weeks of age on
SD were determined as previously described [15].
Liver fat Liver samples were ground in liquid nitrogen and
dissolved in HB buffer (10 mM NaH2PO4, 1 mM EDTA, 1%
polyoxyethylene-10-tridecyl-ether, pH 7.4). The triacylglycerol
concentration was measured with the Randox TR210 kit
(Randox, Wülfrath, Germany) according to the manufacturer’s
instructions.
Microarray Liver RNAwas purified from four animals each
(8 weeks) from B6-WTand B6-Tg(Zfp69) on SD and used for
microarray analysis (Agilent Whole Genome Mouse 4×44K
arrays, Source Bioscience, Berlin, Germany).
Results
C57BL/6J transgenic mice overexpressing Zfp69 In order
to investigate the impact of Zfp69 on glucose homeostasis and
fat distribution, its myc-tagged cDNA fused to the ubiquitin C
promoter was integrated into the ROSA locus of B6 genome
(ESM Fig. 1a). At 8 weeks of age, Zfp69 expression levels
were examined in various tissues of the transgenic mouse line.
As anticipated, Zfp69 was markedly overexpressed in all tis-
sues of the transgenic mice (ESM Fig. 1b), whereas mRNA
levels were below the detection level (Ct value <35 by qPCR)
in B6-WT. This increase in Zfp69 mRNA levels gave rise to
protein levels in liver nuclei that were twofold higher in Zfp69
transgenic mice than in SJL (ESM Fig. 1c).
The Zfp69 transgenic mice developed normally and did not
show any alteration in body weight increment as compared
with B6-WT mice (ESM Fig. 2).
Mild insulin resistance in B6-Tg(Zfp69) mice To examine
the effect of Zfp69 on glucose metabolism, blood glucose and
insulin levels were compared between control and transgenic
mice. Zfp69 overexpression did not result in increased blood
glucose levels in the fed status at any time point (Fig. 1a).
However, plasma insulin levels at 24 weeks of age were
significantly higher in B6-Tg(Zfp69) than in WT mice
(Fig. 1b), whereas total pancreatic insulin content did not dif-
fer between the groups (ESM Fig. 3a). Beta cell area in the
pancreas did not show any difference between the genotypes
(ESM Fig. 3b). Furthermore, glucose and glucose plus palmi-
tate stimulation of isolated islets, as well as potassium chloride
treatment, increased the secretion of insulin from both B6-WT
and B6-Tg(Zfp69) islets (ESM Fig. 3c) without significant
Fig. 1 Increased plasma insulin levels in B6-Tg(Zfp69) mice. (a) Sam-
ples for measurement of randomly fed blood glucose levels were collect-
ed in the morning from mice on SD.White circles, B6-WT; black circles,
B6-Tg(Zfp69). (b) Plasma insulin levels were measured in the
postprandial state at the age of 24 weeks. Data are presented as mean±
SE of 7–11 mice. *p<0.05 by Student’s t test
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differences between genotypes. Glucose clearance during an
OGTT at week 18 was not different between B6-WT and B6-
Tg(Zfp69) mice (Fig. 2a), but the insulin concentration was
significantly increased in B6-Tg(Zfp69) mice (Fig. 2b), sug-
gesting that Zfp69 overexpression causes mild insulin resis-
tance. Additionally, in intraperitoneal GTT (IP-GTT) blood
glucose levels were not different between B6-WT and
B6-Tg(Zfp69) mice (ESM Fig. 4a). However, insulin levels
during IP-GTT showed only a tendency to increase (ESM
Fig. 4b).
Consistent with the assumption of a hepatic insulin resis-
tance, the expression of proteins involved in glucose homeo-
stasis, such as glucose-6-phosphatase (encoded by G6pc) and
phosphoenolpyruvate carboxykinase1 (encoded by Pck1),
was significantly increased in livers of B6-Tg(Zfp69) mice at
week 24 (ESM Fig. 5).
Effect of Zfp69 on glucose metabolism in obese mouse
models Since the diabetogenic effect of the Zfp69 locus re-
quired obesity, we challenged control and B6-Tg(Zfp69) mice
with a HFD, which markedly increased body weight. In addi-
tion, NZO mice were crossed with B6-Tg(Zfp69) mice to pro-
duce obese NZO/B6 F1 progeny overexpressing Zfp69. Like
B6-Tg(Zfp69) mice, NZO/B6-Tg(Zfp69) mice overexpressed
Zfp69 in fat tissues, muscle and liver (ESM Fig. 6a). Blood
glucose in the fed status did not differ between NZO/B6-WT
and NZO/B6-Tg(Zfp69) mice (ESM Fig. 6b). As expected,
the body weight of NZO/B6 F1 mice was twofold higher than
that of B6 mice, with no differences between genotypes (ESM
Fig. 6c), suggesting that Zfp69 overexpression does not alter
growth or fat accumulation.
In order to investigate whether or not Zfp69 expression
causes any alteration in glucose homeostasis, blood glucose
levels and the corresponding insulin levels were measured
after an overnight fast and 2 h after refeeding. Blood glucose
levels did not differ between the genotypes in either condition
(Fig. 3a), but insulin levels were significantly higher in the
postprandial state of 8-week-old B6-Tg(Zfp69) mice on
HFD (Fig. 3b). Interestingly, in week 18, B6-Tg(Zfp69) mice
showed significantly higher fasted insulin concentrations than
B6-WTmice (Fig. 3c), but with no changes in the correspond-
ing blood glucose levels (data not shown). Similarly, NZO/
B6-Tg(Zfp69) mice exhibited a tendency towards higher insu-
lin levels after refeeding (Fig. 3e), whereas the blood glucose
levels were not different between the genotypes (Fig. 3d).
In OGTT of B6-Tg(Zfp69) mice on HFD (week 22) blood
glucose levels were not different (ESM Fig. 7a), whereas cor-
responding insulin levels in Zfp69 transgenic mice tended to
be increased (ESM Fig. 7b). ITTs revealed a tendency towards
increased blood glucose levels in B6-Tg(Zfp69) mice on a
HFD (ESM Fig. 8b) compared with controls, indicating im-
paired insulin sensitivity.
Zfp69 overexpression increases liver fat and plasma triac-
ylglycerol levels and decreases pAKT Lean mice receiving a
HFD as well as obese mice often develop hepatosteatosis
which participates in the development of insulin resistance
[16]. To test whether or not Zfp69 overexpression enhances
hepatic fat storage, we measured the liver triacylglycerol con-
centrations and detected significantly elevated levels, in both
B6-Tg(Zfp69) and NZO/B6-Tg(Zfp69) mice on HFD (Fig. 4a
and d); on SD this effect did not reach statistical significance
(ESM Fig. 9). Lipid droplets, visualised by Plin2 staining
were greater in numbers and larger in size in livers of
B6-Tg(Zfp69) mice on both SD and HFD compared with
WT mice (Fig. 4g). Hepatosteatosis was not due to hyperpha-
gia because food intake did not differ between control and B6-
Tg(Zfp69) mice on HFD (ESM Fig. 10).
The mass of the white gonadal fat pad was not affected by
Zfp69 overexpression in these mice (Fig. 4b and e). However,
plasma triacylglycerol levels were significantly higher in
Zfp69 transgenic mice on B6 and NZO/B6 background
(Fig. 4c and f) compared with controls, as observed in the
Zfp69 overexpressing congenic mice in a previous study
[11]. Furthermore, we evaluated the fat distribution of B6-WT
and B6-Tg(Zfp69) mice at 8 and 16 weeks of age using CT but
did not detect any difference (data not shown).
Fig. 2 Increased insulin levels during OGTT in B6-Tg(Zfp69) mice.
Mice kept on SD until 18 weeks of age were fasted for 6 h before oral
glucose gavage (2 g/kg body weight). (a) Blood glucose and (b) corre-
sponding insulin levels were measured at indicated time points. Area
under the curve (AUC) values of insulin are depicted in the small panel
in (b) (pmol/l×min). White circles, B6-WT; black circles, B6-Tg(Zfp69).
Data are presented as mean±SE of 10–11 animals. *p<0.05, **p<0.01
by Student’s t test
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In order to examine whether or not Zfp69 overexpression
affects hepatic insulin sensitivity, we investigated levels of
pAKT in livers of B6 mice 20 min after intraperitoneal insulin
application. We detected a tendency towards decreased pAKT
levels in B6-Tg(Zfp69) on SD andHFD comparedwith B6-WT
livers (Fig. 5).
Zfp69 suppresses the expression of genes involved in
glucose and lipid metabolism In order to further investi-
gate the effects of Zfp69 overexpression on the molecular
regulation of glucose and lipid metabolism in the liver,
we compared the liver transcriptome of 8-week-old B6-
WT and B6-Tg(Zfp69) mice by a microarray analysis.
Overall, 76 genes met the predefined criteria for greater
than 1.5-fold differential expression (signal intensity on
microarray >90, p<0.05; Student’s t test of four analyses
per group). In livers from B6-Tg(Zfp69) mice, 20 genes
were upregulated and 56 genes were downregulated
(Tables 1 and 2).
Since ZFP69 is an inhibitory regulator of gene expression
by analogy, we further analysed the genes that were sup-
pressed in livers of B6-Tg(Zfp69) mice. According to a liter-
ature survey and a MetaCore-based pathway enrichment
analysis, ten genes with a reduced expression by >25% were
related to diabetes and lipid metabolism (Table 2). The
Zfp69-dependent suppression of nine of these genes, Nampt,
Lpin2, Map2k6, Gys2, Bnip3, Fitm2, Slc2a2, Ppargc1α and
Insr was validated by qPCR (Fig. 6).
Discussion
Zfp69 has been previously suggested to be a causal gene in the
diabetes loci Nidd1 and Nidd/SJL [11]. In this study, we pres-
ent direct evidence in support of this conclusion, and demon-
strate that Zfp69 increases liver fat content and plasma
triacylglycerol concentrations and causes moderate insulin
resistance.
B6-Tg(Zfp69) mice displayed elevated insulin levels in
OGTTs at weeks 18 and 24 compared with B6-WT animals.
Interestingly, IP-GTT did not significantly increase insulin
levels. As IP-GTT by-passes incretin stimulation, in contrast
to OGTT, it can be speculated that Zfp69 overexpression in-
creases incretin release and thereby insulin secretion. Along
these lines, we did not detect an elevated glucose-stimulated
insulin secretion in isolated islets of transgenic mice.
Elevated liver triacylglycerol concentrations, slightly re-
duced hepatic pAKT levels and higher glucose levels during
ITT of HFD fed mice indicate that Zpf69 mediates a moderate
insulin resistance. Accordingly, hepatic expression ofG6pc and
Pck1 was significantly increased, as shown by others in the
insulin-resistant state [17, 18]. The higher liver fat and plasma
triacylglycerol levels could result either from hepatic insulin
resistance or from Zfp69 overexpression in adipose tissue. Sim-
ilarly, in a previous study, we observed hepatosteatosis and
hyperlipidaemia in recombinant congenic mice carrying the
Zfp69 locus of SJL mice and hypothesised that this is due to
reduced lipid storage capacity of adipocytes [11]. However, as
Zfp69 transgenic mice did not exhibit smaller fat pads, elevated
Fig. 3 Increased postprandial insulin levels in obese mouse models ex-
pressing Zfp69. (a) Blood glucose and (b) corresponding insulin levels of
8-week-old B6-WTand B6-Tg(Zfp69) mice were measured after an over-
night fast and 2 h after refeeding. (c) Insulin levels in 16 h fasted status of
B6-WT and B6-Tg(Zfp69) mice fed on an HFD at 18 weeks of age. (d)
Blood glucose and (e) corresponding insulin levels measured in 11-week-
old NZO/B6-WT and NZO/B6-Tg(Zfp69) mice after an overnight fast
and 2 h refeeding.Mice were kept on HFD until the experiment.White bars,
WT mice; black bars, transgenic mice. Data are presented as mean±SE of
9–11 animals. *p<0.05, **p<0.01 by two-way ANOVAwith Bonferroni’s
multiple comparisons test
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plasma triacylglycerol concentrations appear not to be a conse-
quence of elevated lipolysis.
Overall, the phenotype of the transgenic mice is much
weaker than that of recombinant congenic mice carrying the
Zfp69 locus of SJL mice [11]. Contrary to our expectations,
we did not observe hyperglycaemia or beta cell failure in
B6-Tg(Zfp69) or in NZO/B6-Tg(Zfp69) mice. A possible ex-
planation for the mild phenotype could be that Zfp69 needs
other diabetogenic gene variants in order to produce
hyperglycaemia and beta cell failure. We have previously
shown that the introgression of Nidd/SJL encompassing the
intac t Zfp69 in to the NZO background induced
hypoinsulinaemia due to beta cell failure, resulting in
hyperglycaemia [9]. However, when the Nidd/SJL locus was
introgressed into B6-obmice, it caused an altered fat distribu-
tion (hepatosteatosis and a reduced white gonadal fat depot) as
well as mild hyperglycaemia, but not beta cell failure [11],
consistent with the assumption that B6 mice carry diabetes
suppressing genes [6]. Moreover, previous studies showed
thatNidd/SJL interacts withNZO genes (e.g. on chromosomes
1 and 15) that enhance the diabetogenic effect of Nidd/SJL [9,
11].
In addition, the possibility that the Nidd/SJL locus harbours
additional diabetogenic genes that are in linkage disequilibrium
with Zfp69 cannot be discounted. Indeed, a linkage study of an
F2 intercross between B6 and DBA/2 mouse lines with a defi-
ciency in the leptin receptor (db/db) identified an interval of
chromosome 4 that was associated with the traits blood glucose
and plasma triacylglycerols [19], confirming that the region is
responsible for obesity-induced diabetes. Furthermore, from
their genome-wide analysis on an (B6xC3H/HeJ)F2 intercross
with a deficiency in apolipoprotein E, Logsdon et al concluded
that Zfp69 variants are associated with body weight, blood glu-
cose and cholesterol levels [20].
We compared the liver transcriptome of B6-WT and
B6-Tg(Zfp69) mice at an early time point (week 8) before
Fig. 4 Increase in liver fat and
plasma triacylglycerol (TG) levels
in obese mice expressing Zfp69.
B6-WT and transgenic mice fed
with HFD were killed at week
24 at postprandial status. (a) Liver
triacylglycerol levels and (b)
gonadal fat mass (white adipose
tissue [WAT]) was determined. (c)
Plasma triacylglycerol levels were
measured at a postprandial state in
B6 background mice at 12 weeks
of age. NZO/B6 mice (20 weeks
old) fed on an HFD were killed at
postprandial status. (d) Liver
triacylglycerol levels and (e)
gonadal fat mass were
determined. (f) Plasma
triacylglycerol levels of NZO/B6
mice were estimated at
postprandial status at week 23.
Data are presented as mean±SE
of 7–9 animals. *p<0.05,
**p<0.01 by Student’s t test. (g)
Plin2 staining of the liver sections
of B6-WT and B6-Tg(Zfp69).
Livers were taken after 6 h fasting
from mice on SD (20 weeks) and
HFD (22 weeks). Scale bar,
30 μm
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insulin resistance occurs in order to exclude secondary effects
of insulin resistance and to examine the direct effect of Zfp69
overexpression. Microarray analysis revealed that Zfp69 over-
expression decreased the expression of several genes involved
in glucose and lipid metabolism. Interestingly, none of the
upregulated genes in the microarray was related to glucose
or lipid metabolism.
Nampt plays a key role in NAD synthesis, which is need-
ed for the enzymatic activity of sirtuin1 (SIRT1), an impor-
tant regulator of glucose and lipid metabolism [21] and
thereby regulates hepatic triacylglycerol homeostasis [22].
Decreased expression of Nampt could participate in the de-
velopment of hepatic steatosis and insulin resistance by
reducing SIRT1 activity. Hepatic deletion of SIRT1 im-
paired peroxisome proliferator-activated receptor α func-
tion, decreased fatty acid beta-oxidation and caused hepatic
steatosis [23].
Lpin2 is one of three members of the lipin family that act as
phosphatidate phosphatases. These enzymes are required for
glycerolipid biosynthesis and also act as transcriptional co-
activators that regulate expression of lipid metabolising genes.
Interestingly, polymorphisms in the LPIN1 and LPIN2 genes
are associated with traits of metabolic disease, including insu-
lin sensitivity, diabetes and increased blood pressure, as well
as the response to thiazolidinediones [24]. Furthermore, Lpin1
expression levels in adipose tissue and liver are positively
correlated with insulin sensitivity [25]. Thus, a reduced Lpin2
expression in the liver of B6-Tg(Zfp69) micemight affect lipid
metabolism leading to insulin resistance.
Table 1 Upregulated genes in the liver of B6-Tg(Zfp69) mice
Gene bank ID Gene symbol Description Ratio
NM_007919 Cela2a Chymotrypsin-like elastase family, member 2A 6.55
NM_025350 Cpa1 Carboxypeptidase A1 6.00
NM_025583 Ctrb1 Chymotrypsinogen B1 5.55
NM_001033875 Ctrc Chymotrypsin C (caldecrin) 5.52
NM_025469 Clps Colipase, pancreatic 5.23
NM_019738 Nupr1 Nuclear protein 1 3.99
NM_007446 Amy1 Amylase 1, salivary 2.46
NM_024440 Derl3 Der1-like domain family, member 3 2.21
NM_177388 Slc41a2 Solute carrier family 41, member 2 2.13
NM_013769 Tjp3 Tight junction protein 3 1.79
NM_175138 Dnaic1 Dynein, axonemal, intermediate chain 1 1.78
NM_138302 Ecgf1 (also known as Tymp) Endothelial cell growth factor 1 (platelet-derived) 1.66
NM_146116 Tubb2c (also know as Tubb4b) Tubulin, beta 2c 1.65
NM_009777 C1qb Complement component 1, q subcomponent, beta polypeptide 1.57
NM_013612 Slc11a1 Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 1.57
NM_007572 C1qa Complement component 1, q subcomponent, alpha polypeptide 1.55
NM_017372 Lyzs (also known as Lyz2) Lysozyme 1.52
NM_153074 Lrrc25 Leucine rich repeat containing 25 1.51
NM_001037859 Csf1r Colony stimulating factor 1 receptor 1.51
NM_013632 Pnp Purine-nucleoside phosphorylase 1.51
Livers were collected from mice on SD at 8 weeks of age
Genes with a greater than 1.5-fold increased expression are listed
Fig. 5 Slightly reduced hepatic pAKT levels in B6-Tg(Zfp69) mice. B6
mice on SD (20 weeks) were killed 20 min after an intraperitoneal injec-
tion of insulin (1 U). Western blots of pAKT and tAKT in the liver of
B6-WTand B6-Tg(Zfp69) mice on (a) SD and (c) HFD. Quantification of
pAKT/tAKT ratio of (b) SD and (d) HFD fed mice. β-actin was deter-
mined as a loading control. Data are presented asmean±SE of two to four
animals
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Table 2 Downregulated genes in the liver of B6-Tg(Zfp69) mice
Gene bank ID Gene symbol Description Ratio
NM_201256 Eif4ebp3 Eukaryotic translation initiation factor 4E binding protein 3 0.42
NM_032002 Nrg4 Neuregulin 4 0.45
NM_177368 Tmtc2 Transmembrane and tetratricopeptide repeat containing 2 0.50
NM_008898 Por P450 (cytochrome) oxidoreductase 0.52
NM_013631 Pklr Pyruvate kinase liver and red blood cell 0.55a
NM_207665 Olfr144 (also known as Olfr1537) Olfactory receptor 144 0.55
NM_021524 Nampt Nicotinamide phosphoribosyltransferase 0.56b
NM_007812 Cyp2a5 Cytochrome P450, family 2, subfamily a, polypeptide 5 0.56
NM_011943 Map2k6 Mitogen-activated protein kinase 6 0.57c
NM_145572 Gys2 Glycogen synthase 2 0.59d
NM_009760 Bnip3 BCL2/adenovirus E1B interacting protein 1, NIP3 0.60e
NM_011391 Slc16a7 Solute carrier family 16 (monocarboxylic acid transporters), member 7 0.61
NM_172668 Lrp4 Low density lipoprotein receptor-related protein 4 0.63
NM_010361 Gstt2 Glutathione S-transferase, theta 2 0.64
NM_173397 Fitm2 Fat storage-inducing transmembrane protein 2 0.65f
NM_009647 Ak3l1 (also known as Ak4) Adenylate kinase 3 alpha-like 1 0.65
NM_007618 Serpina6 Serine (or cysteine) peptidase inhibitor, clade A, member 6 0.65
NM_007520 Bach1 BTB and CNC homology 1 0.66
NM_172838 Slc16a12 Solute carrier family 16 (monocarboxylic acid transporters), member 12 0.66
NM_031884 Abcg5 ATP-binding cassette, sub-family G (WHITE), member 5 0.67
NM_008772 P2ry1 Purinergic receptor P2Y, G-protein coupled 1 0.68
NM_172563 Hlf Hepatic leukemia factor 0.68
NM_001081131 Dhtkd1 Dehydrogenase E1 and transketolase domain containing 1 0.68
NM_022882 Lpin2 Lipin 2 0.68g
NM_009030 Rbbp4 Retinoblastoma binding protein 4 0.69
NM_026003 Smarca2 SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily a, member 2
0.69
NM_024198 Gpx7 Glutathione peroxidase 7 0.69
NM_008813 Enpp1 Ectonucleotide pyrophosphatase/phosphodiesterase 1 0.70
NM_145076 Trim24 Tripartite motif protein 24 0.71
NM_024289 Osbpl5 Oxysterol binding protein-like 5 0.71
NM_031197 Slc2a2 Solute carrier family 2 (facilitated glucose transporter), member 2 0.71h
NM_008188 Thumpd3 THUMP domain containing 3 0.71
NM_001081260 Tnks1bp1 Tankyrase 1 binding protein 1 0.71
NM_020567 Gmnn Geminin 0.72
NM_028790 Acot12 Acyl-CoA thioesterase 12 0.72
NM_008904 Ppargc1a Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha 0.72i
NM_022722 Dpys Dihydropyrimidinase 0.72
NM_183262 Stk35 Serine/threonine kinase 35 0.72
NM_146078 Ubr2 Ubiquitin protein ligase E3 component n-recognin 2 0.73
NM_011200 Ptp4a1 Protein tyrosine phosphatase 4a1 0.73
NM_198300 Cpeb3 Cytoplasmic polyadenylation element binding protein 3 0.73
NM_009981 Pcyt1a Phosphate cytidylyltransferase 1, choline, alpha isoform 0.73
NM_009738 Bche Butyrylcholinesterase 0.74
NM_178378 Iqcg IQ motif containing G 0.74
NM_011864 Papss2 3′-phosphoadenosine 5′-phosphosulfate synthase 2 0.74
NM_177327 Wwp1 WW domain containing E3 ubiquitin protein ligase 1 0.74
NM_172907 Olfml1 Olfactomedin-like 1 0.74
NM_145823 Pitpnc1 Phosphatidylinositol transfer protein, cytoplasmic 1 0.74
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Gys2 catalyses the rate-limiting step in the synthesis of
glycogen. The liver-specific deletion ofGys2 resulted not only
in a marked reduction of glycogen storage but also in impaired
glucose tolerance [26]. Mitogen-activated protein kinase
(MAPK) kinase 6 (MAP2K6) is a dual-specificity protein
kinase that activates the stress-activated protein p38 MAPK
[27]. In the livers of obese mice, p38 MAPK activity was
markedly reduced compared with that of lean mice [28].
The liver-specific overexpression of constitutively active
MAP2K6 (MKK6Glu) in obese ob/ob mice markedly re-
duced plasma insulin concentrations and improved glu-
cose tolerance [28], indicating that reduced Map2k6 ex-
pression as detected in B6-Tg(Zfp69) mice might impair
glucose homeostasis.
Table 2 (continued)
Gene bank ID Gene symbol Description Ratio
NM_010568 Insr Insulin receptor 0.74j
NM_013505 Dsc2 Desmocollin 2 0.74
NM_001013391 Cpsf6 Cleavage and polyadenylation specific factor 6 0.74
NM_011387 Slc10a1 Solute carrier family 10 (sodium/bile acid cotransporter family), member 1 0.74
NM_007996 Fdx1 Ferredoxin 1 0.74
NM_177321 Mia2 Melanoma inhibitory activity 2 0.74
NM_022996 Ndfip1 Nedd4 family interacting protein 1 0.75
NM_153599 Cdk8 Cyclin-dependent kinase 8 0.75
Livers were collected from mice on SD at 8 weeks of age
Genes with reduced expression by >25% are listed
a–j The ten genes selected by a literature survey and a MetaCore-based pathway enrichment analysis as being related to diabetes and lipid metabolism
Fig. 6 Suppression of hepatic
genes involved in glucose and
lipid metabolism in response to
Zfp69 overexpression. Genes
involved in glucose and lipid
metabolism were selected by
MetaCore-based pathway
enrichment analysis among genes
exhibiting >25% decreased
expression in the liver of B6-
Tg(Zfp69) mice at 8 weeks of age
on SD. (a) Nampt (b) Lpin2 (c)
Map2k6 (d) Gys2 (e) Bnip3 (f)
Slc2a2 (g) Fitm2 (h) Ppargc1α (i)
Insr and (j) Pklr. Each gene is
presented by the signal intensity
on microarray (left graph) and the
expression validation by qPCR
(right graph).White bars, B6-WT;
black bars, B6-Tg(Zfp69). Data
are presented as mean±SE of
three to four animals. *p<0.05,
**p<0.01 by Student’s t test
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Reduced Bnip3 in mice overexpressing Zfp69 can be also
linked to elevated hepatic fat storage because deletion of
Bnip3 in mice resulted in increased lipid synthesis in the liver
[29]. Bnip3 localises to the outer mitochondrial membrane
and plays an important role in mitophagy and mitochondrial
dynamics and is thereby vital in the adaptive response to
changes in energy balance arising from deficiencies in oxygen
or glucose availability [30].
Fitm2 encodes the fat storage-inducing transmembrane
protein2, an evolutionarily conserved protein that is directly
involved in fat storage. It is located in the endoplasmic
reticulum and involved in partition of triacylglycerol into lipid
droplets [31]. In a three-stage association study performed
with an east Asian population FITM2 was shown to associate
with type 2 diabetes [32].
Ppargc1α is a transcriptional coactivator that is a central
inducer of mitochondrial biogenesis [33] and a regulator of
gluconeogenesis [34, 35]. As increased hepatosteatosis was
shown to correlate with reduced Ppargc1α expression [36],
it can be speculated that lower Ppargc1α levels in the liver of
B6-Tg(Zfp69) mice participate in ectopic fat storage and sub-
sequently cause insulin resistance.
The molecular mechanism by which Zfp69 regulates the
expression of target genes remains to be elucidated and further
studies are required to provide direct functional evidence that
Zfp69 modulates these candidates directly. By sequence
homology, Zfp69 is a member of KRAB domain zinc finger
proteins, which are assumed to suppress expression of target
genes [37]. Our microarray results reflect this to some extent,
with considerably more genes downregulated in the liver than
upregulated.
In conclusion, our analysis of the phenotype of transgenic
mice overexpressing Zfp69 indicates that Zfp69 plays a role
lipid metabolism, liver fat accumulation and presumably in
incretin release. Thus, the data are consistent with the conclu-
sion that Zfp69 is a causal gene of the diabetes locusNidd/SJL.
However, the data also suggest that Zfp69 is not the only factor
mediating the diabetogenic effect of this locus.
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